Teadenol B as a Component of Microorganism-Fermented Tea Extract Inhibited Breast Cancers by Promoting Autophagy
Ying Zhao1, Zhang-Gui Ding2,3,4,5,6, Yu-Jie Yan1
1Ministry of Education Laboratory of Combinatorial Biosynthesis and Drug Discovery, School of Pharmaceutical Science, Wuhan University, Wuhan 430071, China.
Abstract:
Breast cancer is a significant threat to life and health, which needs more safe and effective drugs to be explored. Teadenol B is a characteristic chemical component of microbial fermented tea. This study discovered that teadenol B could exhibit obvious inhibitory effects on all four different clinical subtype characteristics of breast cancer cells. Proteomic studies show that deoxycytidine triphosphate deaminase (DCTD), which could block DNA synthesis and repair DNA damage, had the most significant and consistent reduction in all four types of breast cancer cells with the treatment of teadenol B. Considering MDA-MB-231 cells exhibit poor clinical prognosis and displayed substantial statistical differences in KEGG pathway enrichment analysis results, we investigated its impact on the size and growth of MDA-MB-231 triple-negative breast tumors transplanted into nude mice and demonstrated that teadenol B significantly suppressed tumor growth without affecting body weight significantly. Finally, we found that the conversion of LC3-I to LC3-II in MDA-MB-231 increased significantly with teadenol B treatment. This proved that teadenol B could be a strong autophagy promotor, which explained the down-regulation of DCTD to some extent and may be the potential mechanism underlying teadenol B's anti-breast cancer effects. This finding provides new evidence for drinking fermented tea to prevent breast cancer and highlights the potential of teadenol B as a novel therapeutic option for breast cancer prevention and treatment, necessitating further investigations to clarify its exact target and the details involved.
Insights
Teadenol B, found in fermented tea, effectively inhibits breast cancer cell growth by reducing DCTD levels and promoting autophagy. This natural compound shows potential as a novel therapeutic for breast cancer prevention and treatment.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Breast cancer necessitates novel, safe therapeutic agents.
- Microbial fermented tea contains bioactive compounds like Teadenol B.
- Existing treatments require complementary or alternative options.
Purpose of the Study:
- To investigate the anti-breast cancer effects of Teadenol B.
- To elucidate the molecular mechanisms underlying Teadenol B's efficacy.
- To evaluate Teadenol B's therapeutic potential in preclinical models.
Main Methods:
- In vitro studies on four breast cancer cell subtypes.
- Proteomic analysis to identify molecular targets.
- In vivo studies using MDA-MB-231 triple-negative breast tumor xenografts in nude mice.
- Analysis of autophagy markers (LC3-I/LC3-II conversion).
Main Results:
- Teadenol B demonstrated significant inhibitory effects across all tested breast cancer subtypes.
- A consistent and significant reduction in deoxycytidine triphosphate deaminase (DCTD) was observed.
- Teadenol B suppressed MDA-MB-231 tumor growth in vivo without significant impact on body weight.
- Increased LC3-I to LC3-II conversion indicated Teadenol B as an autophagy promoter.
Conclusions:
- Teadenol B exhibits potent anti-breast cancer properties, acting as an autophagy promoter.
- The down-regulation of DCTD by Teadenol B may contribute to its anti-cancer effects.
- Teadenol B represents a promising candidate for breast cancer prevention and therapy, warranting further research.
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Prevention
Some...


